Inflammation plays a central role in the aetiology of many immunologically related diseases, such as infectious disease, osteoarthritis and respiratory disease, as well as neurologic, metabolic and cardiovascular disease and cancer.
As your research uncovers the significant role of biomarkers in normal and disease states, you need a reliable partner for quality assays and consistent performance.
New Merck MILLIPLEX® MAP Human Cancer Autoantibody Panel, a 15-plex customisable panel.
Being the third¹ liquid biopsy test for Biocartis, the newly launched assay, Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only), also marks an important milestone in the partnership with the leading science and technology company Merck².
Biocartis, an innovative molecular diagnostics company, today announces the launch of its second liquid biopsy assay, the Idylla™ ctKRAS Mutation Assay (Research Use Only, RUO), which was developed in partnership with the leading science and technology company Merck1 on Biocartis’ molecular diagnostics platform Idylla™.